Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Moderately to Severely Active Ulcerative Colitis (Phase 2b/3, Japan)
jRCT2080224895Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in autoimmune colitis (9 arms), sponsored by Janssen Pharmaceutical. Started Sep 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224895.